Table 1: Clinical and laboratory characteristic of 98 MPNs at diagnosis according to diagnosis.

IMFMPN-UPVTE value

Number of patients982655na
M/F 8/13/517/925/300.04
Median age, years (range)68 (54–82)69 (43–67)72 (30–85)63 (25–89)0.04
Follow-up days, median (range)885.5 (397–2130)1314 (350–2707)1358.5 (128–5871)2137 (179–4708)0.1
Hb, g/100 mL (range)15.1 (12.1–17.4)16.1 (12.5–19.1)18.0 (14.5–21.5)14.9 (11.1–18.1)0.0001
WBC × 109/L (range)7.43 (5.52–13.82)7.73 (5.4–15.53)10.98 (1.7–19.6)8.3 (3.18–16.71)0.05
Monocytes × 109/L (range)0.48 (0.08–0,89)0.4 (0.3–0.82)0.45 (0.02–1.55)0.45 (0.11–0.78)0.8
Plt × 109/L (range)615 (429–1094)629 (181–1006)481 (134–1745)684 (443–1750)0.0001
JAK2 V617F (%)6/9 (66.6)6/8 (75)26/26 (100)35/55 (63.6)0.0001
JAK2 V617F burden median % (range)40 (5–64)17 (4–40)60 (24–90)14 (5–59)0.0001
EEC (%)6/9 (66.6)6/8 (75)23/26 (88.5)41/55 (74.5)0.1
CGU-MK (%)3/9 (33.3)4/8 (37.5)16/26 (61.5)36/55 (65.5)0.1
CD34 + SP × 109/L (range)0.051 (0.013–0.25)0.021 (0.0046–0.051)0.040 (0.0035–0.5)0.024 (0.0015–0.61)0.07
CD34 + SP (%) (range)0.05 (0.035–0.45)0.03 (0.01–0.09)0.04 (0.01–0.56)0.03 (0.0015–0.27)0.07
Bone marrow cellularity % (range)60 (30–90)40 (20–80)80 (60–95)50 (20–98)0.0001
Single cytogenetic abnormality ( )1/92/82/260/540.3
Complex karyotype ( )0/90/80/261/54
Trisomy ( )0/90/81/260/54
Palpable splenomegaly ( )6/93/816/2615/550.7
Splenic square cm2 (range)50 (26–102)43,5 (37–65)63 (25–200)40 (28–105)0.04
Arterial thromboses ( )5/90/86/2612/550.6
Venous thromboses ( )1/90/86/263/55
Spontaneous haemorrhage ( )0/90/81/261/550.7
Posttraumatic haemorrhage ( )1/90/90/261/55
Cytoreductive treatment ( )7/97/826/2642/550.06